Skip to main content
  • Home
  • Incretin Management in Type 2 Diabetes
background background

THIS CONTENT IS FOR HEALTHCARE PROFESSIONALS ONLY

Incretin Management in Type 2 Diabetes

In this series of videos and downloadable summaries, leading global experts will guide you through how the incretin system works, what happens to it in type 2 diabetes and how to optimise the use of incretin-based agents for better patient outcomes.

Supported by an educational grant from NOVO NORDISK A/S

Discover our Videos and documents

view

Pathophysiology

(2 contents)

Pathophysiology

Diabetes pathophysiology

ENG, SPA, Ger, FRE

author

Silvio Inzucchi

Yale University, School of Medicine

Dr Inzucchi discusses the eight abnormalities leading to diabetes mellitus, the “Ominous Octet”, and current pathophysiologically-based therapies aimed at glycaemic control and prevention of vascular complications in type 2 diabetes.

Pathophysiology

The incretin system & incretin-targeting agents

ENG, SPA, Ger, FRE

author

Silvio Inzucchi

Yale University, School of Medicine

Dr Inzucchi explains how malfunction of incretin hormones leads to type 2 diabetes pathogenesis, and discusses the use of incretin-based treatments, in particular GLP-1 RAs, for diabetes management especially in patients with CVD.

Clinical inertia

(2 contents)

Clinical inertia

Therapeutic inertia in T2DM

ENG, SPA, Ger, FRE

author

Kamlesh Khunti

University of Leicester

Prof Khunti talks about the importance of translating high-quality evidence into clinical practice and avoiding “therapeutic inertia”.

Clinical inertia

Early glycaemic control in T2DM

ENG, SPA, Ger, FRE

author

Kamlesh Khunti

University of Leicester

Prof Khunti highlights the importance of screening and early intensification of antihyperglycaemic agents for better glycaemic control and improved microvascular, macrovascular and mortality outcomes in patients with type 2 diabetes.

Incretin-based glycaemic control

(4 contents)

Incretin-based drugs

The use of GLP-1 RAs in T2DM

ENG, SPA, Ger, FRE

author

Sarah Davies

Woodlands Medical Centre

Dr Davies summaries different guidelines recommendations on the use of newer diabetes drugs (i.e., SGLT-2i, DPP-4i, GLP-1RAs) and describes the patient populations appropriate for each class of therapy.

Incretin-based drugs

Incretin-based drugs: What does the data say?

ENG, SPA, Ger, FRE

author

Sarah Davies

Woodlands Medical Centre

Dr Davies highlights the role of the incretin system in glycaemic control and major differences between GLP-1RAs and DPP-4is and explores recent data from meta-analyses and head-to-head trials on the efficacy of these drug classes

Incretin-based drugs

Incretin-based drugs: Mode of action/delivery & dosing schedule

ENG, SPA, Ger, FRE

author

Su Down

Somerset NHS Foundation Trust

Su Down underlines the role of incretin hormones in regulating glucose haemostasis and describes the mode of action/delivery and dosing schedule of incretin-based therapies through which, the glycemic control in type 2 diabetes is maintained.

Incretin-based drugs

Appropriate prescribing practices

ENG, SPA, FRE, Ger

author

Su Down

Somerset NHS Foundation Trust

Su Down provides insight into the special considerations for safe prescribing of GLP-RAs and DPP-4is, as she describes appropriate patient populations, dose titration, sick day rules, and management of potential adverse events.

Beyond glycaemic control

(2 contents)

Beyond Glycaemic Control

Cardiovascular benefits

ENG, SPA, FRE, Ger

author

Mikhail Kosiborod

Cardiometabolic Center of Excellence , Saint Luke’s Mid America Heart Institute

Dr Kosiborod highlights the recent data on the role of GLP-1 RAs in cardiovascular risk reduction and shares his own experience of how a multidisciplinary approach can maximise guideline-directed care, including the adoption of GLP-1 RAs.

Beyond Glycaemic Control

Weight loss benefits

ENG, SPA, FRE, Ger

author

Mikhail Kosiborod

Cardiometabolic Center of Excellence , Saint Luke’s Mid America Heart Institute

Dr Kosiborod discusses the importance of obesity management in type 2 diabetes and which anti-diabetic agents have proven weight loss benefits. He also highlights the key findings from the STEP trial programme.

Faculty Biographies

Silvio Inzucchi

Yale University, School of Medicine

Dr Inzucchi is a Professor of Medicine at the Yale University School of Medicine in New Haven, where he serves as Clinical Chief of the Section of Endocrinology, Medical Director of the Yale Diabetes Center, and Program Director of the Endocrinology & Metabolism Fellowship. 

View full profile

Kamlesh Khunti

University of Leicester

Prof Khunti is the Professor of Primary Care Diabetes and Vascular Medicine at the University of Leicester and Co-Director of the Leicester Diabetes Centre.  His work has greatly influenced guidelines on the screening and management of people with diabetes.

View full profile

Sarah Davies

Woodlands Medical Centre

Dr Davies graduated from the University of Wales College of Medicine in 2003, initially pursuing a career in medicine, especially diabetes and endocrinology. She then made the move to General Practice and continued her interest in diabetes, completing the Cardiff Postgraduate diploma in diabetes.

View full profile

Su Down

Somerset NHS Foundation Trust

Su Down is a Nurse Consultant in Diabetes and is the Clinical Lead for the Intermediate Diabetes community service in Somerset.  Her Diabetes nursing career started in 1989, when she set up the diabetes specialist nursing service in Yeovil District Hospital.  Su took up the role of Nurse Consulta

View full profile

Mikhail Kosiborod

Cardiometabolic Center of Excellence , Saint Luke’s Mid America Heart Institute

Dr Kosiborod is an internationally recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, and quality care and outcomes. He is a cardiologist, Vice President of Research at Saint Luke's Health System, Director of Cardiometabolic Research

View full profile